Article
Dermatology
Zhen Guo, Qiongyang Liu, Shijie Lan, Ningning Niu, Jianping Gui, Yiqun Zhang, Di Wu
Summary: This study analyzed the epidemiology and clinicopathologic characteristics of melanoma patients in Northeast China. The study found that vascular invasion may be a prognostic factor in melanoma patients. Furthermore, there were significant differences in disease location, pathologic subtype, gene status, and survival prognosis between the population of Northeast China and Caucasian population.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2023)
Article
Multidisciplinary Sciences
Filipa Alves da Costa, Adriana Ramos, Catarina Bernardo, Fabio Cardoso Borges, Ana Costa Miranda
Summary: This is a population-based cohort study conducted in the South Region of Portugal to estimate the incidence of cutaneous malignant melanoma, characterize diagnosed individuals, describe treatment, and estimate survival outcomes. The study found a melanoma incidence rate of 13.36/100,000 inhabitants and a 3-year overall survival rate of 80.54%. The adjusted hazard ratio showed a two-fold increased risk of recurrence/death in the presence of ulcerated tumors.
SCIENTIFIC REPORTS
(2023)
Article
Biochemistry & Molecular Biology
Rita Casadonte, Mark Kriegsmann, Katharina Kriegsmann, Helene Streit, Rolf Ruediger Meliss, Cornelia S. L. Mueller, Joerg Kriegsmann
Summary: This study used proteomic technology to compare the molecular profiles of BRAF and NRAS mutated and wildtype melanoma patients' tissue samples. The results showed molecular differences between BRAF and NRAS mutated melanoma, and accurate identification was possible with an accuracy of 87-89% and 76-79% depending on the classification method.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Multidisciplinary Sciences
Lauren Y. Cheng, Lauren E. Haydu, Ping Song, Jianyi Nie, Michael T. Tetzlaff, Lawrence N. Kwong, Jeffrey E. Gershenwald, Michael A. Davies, David Yu Zhang
Summary: The study demonstrates that the NuProbe VarTrace BRAF sequencing technology can detect BRAF V600 mutations down to 0.20% VAF from FFPE lymph node tissue samples, with high concordance among various methods for samples with VAF>=1% BRAF mutations, but with possible false negatives in IHC. The BDA Sanger method is effective for rapid detection and quantitation of multiple low VAF BRAF mutations.
SCIENTIFIC REPORTS
(2021)
Article
Toxicology
Sowjanya Thatikonda, Venkatesh Pooladanda, Ramya Tokala, Shankaraiah Nagula, Chandraiah Godugu
Summary: Malignant melanoma, a deadly aggressive form of skin cancer, frequently metastasizes to distal organs and is associated with BRAF or NRAS mutations in 30 to 50% of patients. Niclosamide, an FDA-approved anthelmintic drug, has shown strong anticancer properties against various tumors. In this study, the researchers investigated the role of Niclosamide in inhibiting metastatic melanoma in vitro using SK-MEL-2 and SK-MEL-28 cell lines. They found that Niclosamide induces apoptosis and ROS generation, inhibits cell cycle progression, and suppresses metastasis. Furthermore, Niclosamide inhibits key markers involved in the EMT signaling cascade. These findings provide valuable insights into the mechanism of Niclosamide in BRAF/NRAS mutant melanoma cells and its potential as a therapeutic agent.
TOXICOLOGY IN VITRO
(2023)
Article
Oncology
Jonathan M. Loree, Yucai Wang, Muddassir A. Syed, Alexey Sorokin, Oluwadara Coker, Joanne Xiu, Benjamin A. Weinberg, Ari M. Vanderwalde, Anteneh Tesfaye, Victoria M. Raymond, Benjamin Miron, Gabi Tarcic, Ori Zelichov, Russell R. Broaddus, Patrick Kwok Shing Ng, Kang Jin Jeong, Yiu Huen Tsang, Gordon B. Mills, Michael J. Overman, Axel Grothey, John L. Marshall, Scott Kopetz
Summary: The study identified a high prevalence of atypical RAS mutations in colorectal cancer patients, which were associated with poor prognosis. Activating atypical variants were the most common in clinical cohorts, providing the best evidence to guide treatment.
CLINICAL CANCER RESEARCH
(2021)
Article
Chemistry, Medicinal
Xiu-Cai Chen, Gui-Xue Tang, Jing Dai, Le-Tian Dai, Tian-Ying Wu, Wen-Wei Li, Tian-Miao Ou, Zhi-Shu Huang, Jia-Heng Tan, Shuo-Bin Chen
Summary: Mutations in NRAS contribute to tumor formation and resistance to drugs. The development of novel strategies to suppress NRAS for anticancer therapy is urgent, as this protein is usually considered untargetable. Recent research has shown that a G-quadruplex structure in the untranslated region of NRAS mRNA can reduce NRAS translation, providing a potential NRAS suppression strategy. In this study, a cell-based screening method was developed using a G-quadruplex-triggered fluorogenic hybridization probe, and the clinically used agent Octenidine was identified as a potent NRAS repressor. Octenidine inhibited NRAS translation, blocked MAPK and PI3K-AKT signaling, and induced cell cycle arrest, apoptosis, and autophagy. It exhibited better antiproliferative effects compared to clinical antimelanoma agents and could inhibit the growth of NRAS-mutant melanoma in a mouse model. These results suggest that Octenidine may be a promising therapy for NRAS-mutant melanoma.
JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Biochemistry & Molecular Biology
Vlad-Adrian Afrasanie, Mihai-Vasile Marinca, Bogdan Gafton, Teodora Alexa-Stratulat, Alexandra Rusu, Eliza-Maria Froicu, Daniel Sur, Cristian Virgil Lungulescu, Larisa Popovici, Andrei-Vlad Lefter, Irina Afrasanie, Anca-Viorica Ivanov, Lucian Miron, Cristina Rusu
Summary: In this study, the frequency, distribution, coexistence, and clinicopathological and molecular correlations of RAS, BRAF, PIK3CA, and TP53 mutations were investigated in 104 patients with metastatic colorectal cancer from Northeastern Romania. TP53 was the most frequently mutated gene (73.1%), followed by KRAS (45.2%) and PIK3CA (6.7%). The study provides novel insights into genetic variations specific to the population from Northeastern Romania and enables the development of genetic profiles in a developing country with limited access to specialized genetic tests.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Hussein Akil, Mercedes Quintana, Jeremy H. Raymond, Tommy Billoux, Valentin Benboubker, Sophie Besse, Philippe Auzeloux, Veronique Delmas, Valerie Petit, Lionel Larue, Michel D'Incan, Francoise Degoul, Jacques Rouanet
Summary: Targeted radionuclide therapy (TRT) combined with MAPK/ERK inhibitors shows additive efficiency in BRAF and NRAS mutant melanoma cells. TRT has a significant therapeutic effect on NRAS(Q61K) mutated melanoma and reduces metastasis capacity.
Article
Oncology
Angelika Bickel, Stefan Diem, Lukas Flatz, Bjorn Stinn, Marco Siano
Summary: Standard treatment for advanced melanoma, including dacarbazine and interleukin-2, has low response rates and significant toxicity. New treatments such as immunotherapy and targeted therapy for patients with a BRAF mutation have shown promise, but options for patients with a NRAS mutation are limited.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
(2021)
Article
Oncology
Gregory J. Riely, Egbert F. Smit, Myung-Ju Ahn, Enriqueta Felip, Suresh S. Ramalingam, Anne Tsao, Melissa Johnson, Francesco Gelsomino, Raymond Esper, Ernest Nadal, Michael Offin, Mariano Provencio, Jeffrey Clarke, Maen Hussain, Gregory A. Otterson, Ibiayi Dagogo-Jack, Jonathan W. Goldman, Daniel Morgensztern, Ann Alcasid, Tiziana Usari, Paul Wissel, Keith Wilner, Nuzhat Pathan, Svitlana Tonkovyd, Bruce E. Johnson
Summary: The combination of encorafenib and binimetinib showed clinical efficacy and acceptable safety in patients with BRAF(V600E)-mutant metastatic NSCLC.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Lavinia Spain, Alexander Coulton, Irene Lobon, Andrew Rowan, Desiree Schnidrig, Scott T. C. Shepherd, Benjamin Shum, Fiona Byrne, Maria Goicoechea, Elisa Piperni, Lewis Au, Kim Edmonds, Eleanor Carlyle, Nikki Hunter, Alexandra Renn, Christina Messiou, Peta Hughes, Jaime Nobbs, Floris Foijer, Hilda van den Bos, Rene Wardenaar, Diana C. J. Spierings, Charlotte Spencer, Andreas M. Schmitt, Zayd Tippu, Karla Lingard, Lauren Grostate, Kema Peat, Kayleigh Kelly, Sarah Sarker, Sarah Vaughan, Mary Mangwende, Lauren Terry, Denise Kelly, Jennifer Biano, Aida Murra, Justine Korteweg, Charlotte Lewis, Molly O'Flaherty, Anne-Laure Cattin, Max Emmerich, Camille L. Gerard, Husayn Ahmed Pallikonda, Joanna Lynch, Robert Mason, Aljosja Rogiers, Hang Xu, Ariana Huebner, Nicholas McGranahan, Maise Al Bakir, Jun Murai, Cristina Naceur-Lombardelli, Elaine Borg, Miriam Mitchison, David A. Moore, Mary Falzon, Ian Proctor, Gordon W. H. Stamp, Emma L. Nye, Kate Young, Andrew J. S. Furness, Lisa Pickering, Ruby Stewart, Ula Mahadeva, Anna Green, James Larkin, Kevin Litchfield, Charles Swanton, Mariam Jamal-Hanjani, Samra Turajlic
Summary: Understanding the evolutionary pathways and resistance mechanisms of melanoma is crucial for improving outcomes. This study provides a comprehensive analysis of advanced melanoma, revealing the diverse strategies used by melanoma to evade treatment and the immune system.
Article
Multidisciplinary Sciences
Patricia M. LoRusso, Aleksandar Sekulic, Jeffrey A. Sosman, Winnie S. Liang, John Carpten, David W. Craig, David B. Solit, Alan H. Bryce, Jeffrey A. Kiefer, Jessica Aldrich, Sara Nasser, Rebecca Halperin, Sara A. Byron, Mary Jo Pilat, Scott A. Boerner, Diane Durecki, William P. D. Hendricks, Daniel Enriquez, Tyler Izatt, Jonathan Keats, Christophe Legendre, Svetomir N. Markovic, Amy Weise, Fatima Naveed, Jessica Schmidt, Gargi D. Basu, Shobana Sekar, Jonathan Adkins, Erica Tassone, Karthigayini Sivaprakasam, Victoria Zismann, Valerie S. Calvert, Emanuel F. Petricoin, Leslie Anne Fecher, Christopher Lao, J. Paul Eder, Nicholas J. Vogelzang, Jane Perlmutter, Mark Gorman, Barbara Manica, Lisa Fox, Nicholas Schork, Daniel Zelterman, Michelle DeVeaux, Richard W. Joseph, C. Lance Cowey, Jeffrey M. Trent
Summary: Combination BRAF and MEK inhibitors show high efficacy in treating cutaneous metastatic melanomas with BRAF(V600) mutations, but targeted agents are less effective for BRAF(V600)wild-type metastatic melanomas. The study highlights the importance of comprehensive genomic profiling and the need for further development of molecularly-driven therapies for metastatic melanomas.
Article
Oncology
Lir Beck, Michal Harel, Shun Yu, Ettai Markovits, Ben Boursi, Gal Markel, Tamar Geiger
Summary: The study identified associations between the proteomic profiles of metastatic melanoma patients and clinical information such as survival and immunotherapy response, particularly highlighting the correlation between lung metastases and better immunotherapy response. Analysis of BRAF status and treatment history provided insights into the impact on immunotherapy response and suggested potential for improved treatment efficacy through combination therapy.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Piotr Rutkowski, Patrick Pauwels, Joseph Kerger, Bart Jacobs, Geert Maertens, Valerie Gadeyne, Anne Thielemans, Katrien de Backer, Bart Neyns
Summary: The choice of cancer drugs for advanced melanoma treatment depends on gene alterations in the patient's tumor. Blood samples can reliably determine gene alterations, offering a convenient and fast option for testing. This study suggests that using blood samples for testing could be a less invasive and quick alternative to identify BRAF mutation status in melanoma patients.
Article
Dermatology
K. Isaksson, R. Mikiver, H. Eriksson, J. Lapins, K. Nielsen, C. Ingvar, J. Lyth
Summary: This study investigated melanoma-specific survival in patients with thin CMM in Sweden and found that MSS was excellent, not supporting more extended follow-up programs beyond current recommendations.
BRITISH JOURNAL OF DERMATOLOGY
(2021)
Article
Oncology
Hildur Helgadottir, Karolin Isaksson, Ildiko Fritz, Christian Ingvar, Jan Lapins, Veronica Hoiom, Julia Newton-Bishop, Hakan Olsson
Summary: This study reports a continuous increase in the incidence of subsequent primary melanoma over the past 5 decades, with a steady increase in frequency, incidence rates, and standardized incidence ratios. This rise was independent of age, sex, invasiveness, or site of the melanoma. Additionally, the frequency of patients diagnosed with more than 2 melanomas also significantly increased over the years.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2021)
Article
Obstetrics & Gynecology
Lieske H. Schrijver, Antonis C. Antoniou, Hakan Olsson, Thea M. Mooij, Marie-Jose Roos-Blom, Leyla Azarang, Julian Adlard, Munaza Ahmed, Daniel Barrowdale, Rosemarie Davidson, Alan Donaldson, Ros Eeles, D. Gareth Evans, Debra Frost, Alex Henderson, Louise Izatt, Kai-Ren Ong, Valerie Bonadona, Isabelle Coupier, Laurence Faivre, Jean-Pierre Fricker, Paul Gesta, Klaartje van Engelen, Agnes Jager, Fred H. Menko, Marian J. E. Mourits, Christian F. Singer, Yen Y. Tan, Lenka Foretova, Marie Navratilova, Rita K. Schmutzler, Carolina Ellberg, Anne-Marie Gerdes, Trinidad Caldes, Jacques Simard, Edith Olah, Anna Jakubowska, Johanna Rantala, Ana Osorio, John L. Hopper, Kelly-Anne Phillips, Roger L. Milne, Mary Beth Terry, Catherine Nogues, Christoph Engel, Karin Kast, David E. Goldgar, Flora E. van Leeuwen, Douglas F. Easton, Nadine Andrieu, Matti A. Rookus
Summary: The lack of treatments for obstetrical complications is mainly due to the challenges of drug development during pregnancy, requiring significant investments and commitment to research. Addressing this need requires collaboration from all stakeholders to advance effective and safe treatments for obstetrical syndromes.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
(2021)
Article
Oncology
Hanna Eriksson, Kari Nielsen, Ismini Vassilaki, Jan Lapins, Rasmus Mikiver, Johan Lyth, Karolin Isaksson
Summary: The study reveals an increasing trend in the age-standardised incidence of invasive cutaneous melanoma in Sweden since the 2000s, possibly due to more effective secondary prevention measures and increased awareness of melanoma.
Article
Dermatology
Johan Kappelin, Adele C. Green, Asa Ingvar, Ingela Ahnlide, Kari Nielsen
Summary: The incidence rates of basal cell carcinoma in Sweden are relatively high and increasing, with more pronounced trends in women and aggressive BCC subtypes. The highest incidence was in elderly individuals, with the head and neck being the most common tumor site.
BRITISH JOURNAL OF DERMATOLOGY
(2022)
Article
Dermatology
Oskar Karlsson, Oskar Hagberg, Kari Nielsen, John Paoli, Asa Ingvar
Summary: Individuals at high risk of developing skin cancer exhibit suboptimal sun exposure habits and harmful traveling behaviors. It is recommended that future skin cancer campaigns provide information on accurate sun protection behavior during sunny holidays and associated risk factors. Some risk factors, such as childhood sunburns, numerous common and large/atypical nevi, as well as family history of skin cancer, appear to be less recognized by the population.
DERMATOLOGY PRACTICAL & CONCEPTUAL
(2021)
Article
Dermatology
Isabelle Krakowski, Henrike Habel, Kari Nielsen, Christian Ingvar, Therese M. L. Andersson, Ada Girnita, Karin E. Smedby, Hanna Eriksson
Summary: This study investigated the association between metformin use and survival in diabetic patients with cutaneous melanoma. The results showed that metformin use was associated with improved overall survival regardless of timing and followed a dose-response pattern. However, no association was found between metformin use and melanoma-specific survival.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
Sofi Vikstrom, Rasmus Mikiver, Jan Lapins, Kari Nielsen, Ismini Vassilaki, Johan Lyth, Karolin Isaksson, Hanna Eriksson
Summary: The 5-year melanoma-specific survival rate has improved in Sweden from 1990 to 2020, particularly in the period of 2011-2020. The introduction of new systemic therapies may be associated with this improvement.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Oncology
Johan Lyth, Rasmus Mikiver, Kari Nielsen, Christian Ingvar, Roger Olofsson Bagge, Karolin Isaksson
Summary: This study describes a prognostic instrument for patients with cutaneous melanoma and evaluates its potential as a clinical device for treatment decisions. The prognostic instrument successfully created probabilities for over 30,000 prognostic groups and provides more representative and up-to-date prognostic information for Swedish patients with primary melanoma.
Article
Oncology
Helena Nystrom, Mats Jonsson, Mef Nilbert, Ana Carneiro
Summary: Immunological landscape of soft tissue sarcoma was characterized, revealing a predominance of tumor-infiltrating macrophages over lymphocytes. CD163-positive macrophages were associated with tumor necrosis and predicted an increased risk of metastasis. CD20-positive B cells were scarce in soft tissue sarcoma and correlated with improved overall survival.
Article
Oncology
Vasu R. Sah, Henrik Jespersen, Joakim Karlsson, Lisa M. Nilsson, Mattias Bergqvist, Iva Johansson, Ana Carneiro, Hildur Helgadottir, Max Levin, Gustav Ullenhag, Anders Stahlberg, Roger Olofsson Bagge, Jonas A. Nilsson, Lars Ny
Summary: The 2-year follow-up of the PEMDAC trial showed that patients with high levels of CCL21 in blood had better treatment response and survival. The expression of CCL21 in tumors and the presence of TLS-like regions were also associated with longer survival.
CANCER RESEARCH COMMUNICATIONS
(2023)
Article
Primary Health Care
Jonas Ingvar, Kari Nielsen, Asa Ingvar
Summary: This study aimed to investigate factors related to omitted total body skin examination (TBSE) in the diagnostics of skin cancer using teledermoscopy (TDS). The study found that older age, female gender, primary reason for seeking care not being specifically for a complete skin check, and being examined by a female physician were associated with a higher risk of omitting TBSE.
Meeting Abstract
Dermatology
Katharine Hopkins, Kari Nielsen, Karim Saleh, Johan Palmgren, Asa Ingvar, Valdis Thorhallsdottir
ACTA DERMATO-VENEREOLOGICA
(2022)
Meeting Abstract
Dermatology
Kari Nielsen
ACTA DERMATO-VENEREOLOGICA
(2022)
Meeting Abstract
Oncology
Carl Jacob Holmberg, Rasmus Mikiver, Karolin Isaksson, Kari Nielsen, Christian Ingvar, Johan Lyth, Roger Olofsson Bagge
ANNALS OF SURGICAL ONCOLOGY
(2022)